Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | EEF2K | O00418 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6372519 | 0.88 | KCNH2 (0.41) | ALDH1A1OPRL1KMT2AKCNH2 | |
| SCHEMBL6371180 | 0.83 | KCNH2 (0.33) | ALDH1A1OPRL1EEF2KMEN1LMNA | |
| SCHEMBL6370734 | 0.83 | KCNH2 (0.43) | KCNH2 | |
| SCHEMBL6372358 | 0.82 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL6371072 | 0.80 | EEF2K (0.35) | ALDH1A1OPRL1EEF2KMEN1LMNA | |
| SCHEMBL6371429 | 0.78 | TK1 (0.36) | ALDH1A1EEF2KMEN1LMNAKMT2A | |
| SCHEMBL6370154 | 0.78 | TK1 (0.36) | ALDH1A1EEF2KMEN1LMNAKMT2A | |
| SCHEMBL6371069 | 0.77 | EEF2K (0.34) | ALDH1A1OPRL1EEF2KMEN1LMNA | |
| SCHEMBL5450730 | 0.77 | JAK2 (0.38) | ALDH1A1EEF2KKCNH2JAK2JAK1 | |
| SCHEMBL6377844 | 0.76 | KCNH2 (0.41) | ALDH1A1OPRL1EEF2KMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050096278-A1 | Antibacterial agents | ELLSWORTH EDMUND L (US) | 2005-05-05 | — | — | US | claimed |
| WO-2005026145-A2 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050096278-A1 | Antibacterial agents | ELLSWORTH EDMUND L (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005026145-A2 | QUINOLONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096278-A1 | Antibacterial agents | MRPL21, FBL, SDHA | ALDH1A1 1200/4885OPRL1 2621/4885EEF2K 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.